Evaluation of Cannabinoid Type 2 Receptor Expression and Pyridine-based Radiotracers in Brains from a Mouse Model of Alzheimer's Disease

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2022 Oct 17

PMID 36248003

Authors

Vasil Kecheliev

Francesco Spinelli

Adrienne Herde

Ahmed Haider

Achi Haider

Linjing Mu

Jan Klohs

Simon M Ametamey

Ruiqing Ni

Affiliations

Soon will be listed here.

Abstract

Neuroinflammation plays an important role in the pathophysiology of Alzheimer's disease. The cannabinoid type 2 receptor (CBR) is an emerging target for neuroinflammation and therapeutics of Alzheimer's disease. Here, we aim to assess the alterations in brain CBR levels and evaluate novel CBR imaging tracers in the arcAß mouse model of Alzheimer's disease amyloidosis. Immunohistochemical staining for amyloid-ß deposits (6E10), microgliosis (anti-Iba1 and anti-CD68 antibodies), astrocytes (GFAP) and the anti-CBR antibody was performed on brain slices from 17-month-old arcAß mice. Autoradiography using the CBR imaging probes [F]RoSMA-18-d6, [C]RSR-056, and [C]RS-028 and mRNA analysis were performed in brain tissue from arcAß and non-transgenic littermate (NTL) mice at 6, 17, and 24 months of age. Specific increased CBR immunofluorescence intensities on the increased number of GFAP-positive astrocytes and Iba1-positive microglia were detected in the hippocampus and cortex of 17-month-old arcAß mice compared to NTL mice. CBR immunofluorescence was higher in glial cells inside 6E10-positive amyloid-ß deposits than peri-plaque glial cells, which showed low background immunofluorescence in the hippocampus and cortex of 17-month-old arcAß mice. autoradiography showed that the specific binding of [F]RoSMA-18-d6 and [C]RSR-056 was comparable in arcAß and NTL mice at 6, 17, and 24 months of age. The level of mRNA expression in the brain was not significantly different between arcAß and NTL mice at 6, 17, or 24 months of age. In conclusion, we demonstrated pronounced specific increases in microglial and astroglial CBR expression levels in a mouse model of AD-related cerebral amyloidosis, emphasizing CBR as a suitable target for imaging neuroinflammation.

Citing Articles

A Comprehensive Exploration of the Multifaceted Neuroprotective Role of Cannabinoids in Alzheimer's Disease across a Decade of Research.

Tyrakis P, Agridi C, Kourti M Int J Mol Sci. 2024; 25(16).

PMID: 39201317 PMC: 11354546. DOI: 10.3390/ijms25168630.

PET imaging of neuroinflammation: any credible alternatives to TSPO yet?.

Chauveau F, Winkeler A, Chalon S, Boutin H, Becker G Mol Psychiatry. 2024; 30(1):213-228.

PMID: 38997465 DOI: 10.1038/s41380-024-02656-9.

NRF2 Deficiency Promotes Ferroptosis of Astrocytes Mediated by Oxidative Stress in Alzheimer's Disease.

Tang Z, Chen Z, Guo M, Peng Y, Xiao Y, Guan Z Mol Neurobiol. 2024; 61(10):7517-7533.

PMID: 38401046 DOI: 10.1007/s12035-024-04023-9.

Neuroprotection and Beyond: The Central Role of CB1 and CB2 Receptors in Stroke Recovery.

Bietar B, Tanner S, Lehmann C Int J Mol Sci. 2023; 24(23).

PMID: 38069049 PMC: 10705908. DOI: 10.3390/ijms242316728.

References

Modemann D, Mahardhika A, Yamoune S, Kreyenschmidt A, Maass F, Kremers S . Development of high-affinity fluorinated ligands for cannabinoid subtype 2 receptor, and in vitro evaluation of a radioactive tracer for imaging. Eur J Med Chem. 2022; 232:114138. DOI: 10.1016/j.ejmech.2022.114138. View

Cristino L, Bisogno T, Di Marzo V . Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2019; 16(1):9-29. DOI: 10.1038/s41582-019-0284-z. View

Knobloch M, Farinelli M, Konietzko U, Nitsch R, Mansuy I . Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci. 2007; 27(29):7648-53. PMC: 6672892. DOI: 10.1523/JNEUROSCI.0395-07.2007. View

Biechele G, Wind K, Blume T, Sacher C, Beyer L, Eckenweber F . Microglial activation in the right amygdala-entorhinal-hippocampal complex is associated with preserved spatial learning in App mice. Neuroimage. 2021; 230:117707. DOI: 10.1016/j.neuroimage.2020.117707. View

Heneka M, Carson M, El Khoury J, Landreth G, Brosseron F, Feinstein D . Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14(4):388-405. PMC: 5909703. DOI: 10.1016/S1474-4422(15)70016-5. View

Aso E, Juves S, Maldonado R, Ferrer I . CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J Alzheimers Dis. 2013; 35(4):847-58. DOI: 10.3233/JAD-130137. View

Hassan A, Park K, Kim H, Lee H, Kwon Y, Hwang J . Fluorinated CRA13 analogues: Synthesis, in vitro evaluation, radiosynthesis, in silico and in vivo PET study. Bioorg Chem. 2020; 99:103834. DOI: 10.1016/j.bioorg.2020.103834. View

Gundel D, Deuther-Conrad W, Ueberham L, Kaur S, Otikova E, Teodoro R . Structure-Based Design, Optimization, and Development of [F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET. J Med Chem. 2022; 65(13):9034-9049. DOI: 10.1021/acs.jmedchem.2c00256. View

Li Y, Kim J . Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus. Neuroscience. 2015; 311:253-67. PMC: 4917208. DOI: 10.1016/j.neuroscience.2015.10.041. View

10.

Ni R, Rudin M, Klohs J . Cortical hypoperfusion and reduced cerebral metabolic rate of oxygen in the arcAβ mouse model of Alzheimer's disease. Photoacoustics. 2018; 10:38-47. PMC: 5909030. DOI: 10.1016/j.pacs.2018.04.001. View

11.

Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland T . A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. 2017; 169(7):1276-1290.e17. DOI: 10.1016/j.cell.2017.05.018. View

12.

Vidal-Palencia L, Ramon-Duaso C, Gonzalez-Parra J, Busquets-Garcia A . Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice. Front Pharmacol. 2022; 13:864591. PMC: 8971609. DOI: 10.3389/fphar.2022.864591. View

13.

Haider A, Gobbi L, Kretz J, Ullmer C, Brink A, Honer M . Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. J Med Chem. 2020; 63(18):10287-10306. DOI: 10.1021/acs.jmedchem.0c00778. View

14.

Reusch N, Ravichandran K, Olabiyi B, Komorowska-Muller J, Hansen J, Ulas T . Cannabinoid receptor 2 is necessary to induce toll-like receptor-mediated microglial activation. Glia. 2021; 70(1):71-88. DOI: 10.1002/glia.24089. View

15.

Horti A, Gao Y, Ravert H, Finley P, Valentine H, Wong D . Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg Med Chem. 2010; 18(14):5202-7. PMC: 2903661. DOI: 10.1016/j.bmc.2010.05.058. View

16.

Rapic S, Backes H, Viel T, Kummer M, Monfared P, Neumaier B . Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. Neurobiol Aging. 2012; 34(1):351-4. DOI: 10.1016/j.neurobiolaging.2012.04.016. View

17.

Koppel J, Vingtdeux V, Marambaud P, dAbramo C, Jimenez H, Stauber M . CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. Mol Med. 2014; 20:29-36. PMC: 3951462. DOI: 10.2119/molmed.2013.00140.revised. View

18.

Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, Amit I . Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell. 2018; 173(5):1073-1081. DOI: 10.1016/j.cell.2018.05.003. View

19.

Meletta R, Slavik R, Mu L, Rancic Z, Borel N, Schibli R . Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [C]RS-016 targeting CB2 in atherosclerosis. Nucl Med Biol. 2017; 47:31-43. DOI: 10.1016/j.nucmedbio.2017.01.001. View

20.

Sierra S, Luquin N, Rico A, Gomez-Bautista V, Roda E, Dopeso-Reyes I . Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct. 2014; 220(5):2721-38. PMC: 4549378. DOI: 10.1007/s00429-014-0823-8. View